This PubMed-indexed article is titled "Response and survival in unresectable in‑transit metastatic melanoma according to treatment strategy" and is published in European Journal of Cancer. The article is listed as Epub 21 June 2026 with journal citation 2026 Aug 26:244:116889. DOI: 10.1016/j.ejca.2026.116889. PubMed PMID for retrieval is 42335571. The PubMed entry indicates the article is available as a free article and provides a publisher link for full-text access.
The article addresses outcomes—specifically response and survival—for patients with unresectable in‑transit metastatic melanoma, comparing those outcomes across different treatment strategies. "In‑transit metastases" refers to cutaneous or subcutaneous metastases occurring between the primary melanoma and the regional lymph nodes; when deemed unresectable, these lesions present a management challenge and may be treated with locoregional therapies, systemic immunotherapy, targeted therapy, isolated limb perfusion/infusion, intralesional agents, radiotherapy, or combinations thereof. The PubMed record establishes the focus on comparative outcomes but does not contain the granular clinical data or comparative groups within the supplied text.
The article is authored by Cato Boreel et al., representing a large, multi‑institutional group primarily from the Netherlands. Affiliations listed on the PubMed page include the Scientific Bureau of the Dutch Institute for Clinical Auditing and numerous departments of Medical Oncology, Surgical Oncology, Dermatology, Biomedical Data Sciences, and related clinical services across Dutch university medical centres and cancer institutes. The corresponding author and electronic contact is provided in the PubMed entry (C.D.M. Boreel, with institutional email noted in the full record).
The PubMed entry provides the following verifiable bibliographic details present in the supplied source:
These metadata confirm provenance and allow retrieval of the full manuscript through publisher links or PubMed tools.
The PubMed page links to Elsevier Science full‑text options indicating access routes to the complete article. However, the portion of the PubMed page supplied here does not include the article abstract text, figures, tables, or the full methods and results. Therefore this rewritten summary does not present study data that were not included in the source excerpt.
The supplied PubMed content does not include the study abstract or the manuscript body. Consequently, the following key elements are not reported in the provided source and cannot be summarized from it:
Because these items are absent from the source excerpt, they are explicitly not included below and must be obtained from the full text for accurate clinical appraisal.
This summary is limited to bibliographic and topic-level information present on the PubMed record provided. The absence of the abstract and the manuscript text in the supplied material means no clinical outcomes, numerical results, or evidence-based conclusions can be reported here. Readers should not rely on this entry alone for treatment decisions or guideline development.
The article appears to directly address comparative outcomes by treatment strategy for unresectable in‑transit metastatic melanoma, a clinically relevant question for oncologists and melanoma specialists.
To derive practice‑relevant conclusions (e.g., which treatments are associated with higher response rates or longer survival), clinicians and guideline developers should obtain and review the full Eur J Cancer article via the DOI/publisher link or institutional access.
Key elements to verify in the full text include study design, patient selection, treatment definitions, outcome measures (response criteria and survival endpoints), statistical analyses, and safety data.
If the full manuscript supports robust comparative findings, those data could inform multidisciplinary decision-making about locoregional versus systemic approaches for unresectable in‑transit disease. Until the full results are reviewed, no treatment preference or recommendation can be made based solely on the PubMed metadata.
The PubMed entry includes a publisher link under "Full text links". For access, use the DOI (10.1016/j.ejca.2026.116889) or visit the European Journal of Cancer via institutional or personal subscription, open‑access options, or interlibrary services. The PubMed PMID (42335571) may also be used to retrieve the full entry and any available abstracts or links.
The supplied source establishes that a multicentre Dutch research group published a study in Eur J Cancer in 2026 examining response and survival for unresectable in‑transit metastatic melanoma according to treatment strategy. The PubMed excerpt contains bibliographic and authorship details but does not include the abstract or study data. For clinical application or evidence synthesis, consult the full published article; this summary intentionally refrains from inferring results or conclusions that are not present in the provided source.